NP_002463.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
222,763 Da
NCBI Official Full Name
myosin-8
NCBI Official Synonym Full Names
myosin heavy chain 8
NCBI Official Synonym Symbols
DA7; MyHC-pn; gtMHC-F; MyHC-peri [Similar Products]
NCBI Protein Information
myosin-8
UniProt Protein Name
Myosin-8
UniProt Synonym Protein Names
Myosin heavy chain 8; Myosin heavy chain, skeletal muscle, perinatal; MyHC-perinatal
UniProt Synonym Gene Names
UniProt Entry Name
MYH8_HUMAN
NCBI Summary for MYH8
Myosins are actin-based motor proteins that function in the generation of mechanical force in eukaryotic cells. Muscle myosins are heterohexamers composed of 2 myosin heavy chains and 2 pairs of nonidentical myosin light chains. This gene encodes a member of the class II or conventional myosin heavy chains, and functions in skeletal muscle contraction. This gene is predominantly expressed in fetal skeletal muscle. This gene is found in a cluster of myosin heavy chain genes on chromosome 17. A mutation in this gene results in trismus-pseudocamptodactyly syndrome. [provided by RefSeq, Sep 2009]
UniProt Comments for MYH8
MYH8: Muscle contraction. Defects in MYH8 are a cause of Carney complex variant (CACOV). Carney complex is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas. Familial cardiac myxomas are associated with spotty pigmentation of the skin and other phenotypes, including primary pigmented nodular adrenocortical dysplasia, extracardiac (frequently cutaneous) myxomas, schwannomas, and pituitary, thyroid, testicular, bone, ovarian, and breast tumors. Cardiac myxomas do not develop in all patients with the Carney complex, but affected patients have at least two features of the complex or one feature and a clinically significant family history. Defects in MYH8 are a cause of distal arthrogryposis type (DA7). A hereditary distal arthrogryposis characterized by an inability to open the mouth fully (trismus) and pseudocamptodactyly in which wrist dorsiflexion, but not volarflexion, produces involuntary flexion contracture of distal and proximal interphalangeal joints. Such hand and jaw contractures are caused by shortened flexor muscle-tendon units. Similar lower-limb contractures also produce foot deformity. The trismus-pseudocamptodactyly syndrome is a morbid autosomal dominant trait with variable expressivity but high penetrance. In these patients, trismus complicates dental care, feeding during infancy, and intubation for anesthesia, and the pseudocamptodactyly impairs manual dexterity, with consequent occupational and social disability. Many patients require surgical correction of contractures.
Protein type: Motility/polarity/chemotaxis; Motor
Chromosomal Location of Human Ortholog: 17p13.1
Cellular Component: cytoplasm; cytosol; sarcomere
Molecular Function: actin filament binding; ATP binding; ATPase activity; microfilament motor activity; myosin light chain binding; myosin phosphatase activity
Biological Process: ATP metabolic process; muscle filament sliding; skeletal muscle contraction
Disease: Arthrogryposis, Distal, Type 7; Carney Complex Variant
Research Articles on MYH8
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-MYH8 antibody
Pathways associated with anti-MYH8 antibody
Diseases associated with anti-MYH8 antibody
Organs/Tissues associated with anti-MYH8 antibody
|